Drugs & Therapy Perspectives

, Volume 34, Issue 11, pp 534–538 | Cite as

Monitoring therapeutic colistin concentrations in critically ill patients admitted to a tertiary care hospital

  • Sriramulu Manivannan Vithunes
  • Sathiyanathan Priyanka
  • Johncy Jose
  • Nitha Thankam Sajeev
  • Ranganathan Hariprasad
  • Gurusamy Venu
  • Karthik Siram
  • Veintramuthu SankarEmail author
Original Research Article



The purpose of this study was to determine the optimal dosage of colistin according to colistin concentrations and the creatinine clearance rate (CLCR) in 21 critically ill haemodialysis and non-haemodialysis patients with Gram-negative bacterial infections admitted to a tertiary care hospital in India.

Methodology and design

Blood samples were collected from patients after the fourth dose of colistin to measure the trough concentrations of colistin using high-pressure liquid chromatography. Additionally, CLCR was calculated using the Cockcroft-Gault equation, and serum creatinine values were used to assess nephrotoxicity.


The optimum therapeutic range of colistin in plasma was considered to be 5–17 µg/ml. Three haemodialysis patients had high plasma colistin concentrations of 25.27 ± 6.65 µg/ml and three non-haemodialysis patients had high colistin concentrations of 36.56 ± 17.26 µg/ml. Six patients had a CLCR value < 20 ml/min. The dosage of colistin in patients with high colistin plasma concentrations and low CLCR was reviewed.


For this group of patients, based on trough concentrations of colistin, CLCR, and clinician’s clinical experience, a reduction of colistin dosage in haemodialysis patients and non-haemodialysis patients, respectively, was suggested to lower elevated plasma colistin concentrations. This dosage reduction may reduce the signs associated with nephrotoxicity and promote improvements in patient life and colistin-related outcomes.



The authors express their sincere gratitude to Dr. Sivaram Hariharan, Department of Pharmaceutical Chemistry, PSG College of Pharmacy, for English proof reading and editing this research work.

Compliance with ethical standards

The study was carried out in patients admitted for routine treatment who provided consent and after obtaining approval from the PSG Institute of Medical Sciences and Research Institutional Human Ethics Committee (Ref: Project No. 14/460). No remuneration was provided to the patients.


No sources of funding were used to conduct this study or prepare this manuscript.

Conflicts of interest

SMV, SP, JJ, NTS, RH, GV, KS, VS have no conflicts of interest that are directly relevant to the content of this article.


  1. 1.
    Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88–94.CrossRefGoogle Scholar
  2. 2.
    Landersdorfer CB, Nation RL. Colistin: how should it be dosed for the critically ill? Semin Respir Crit Care Med. 2015;36:126–35.CrossRefGoogle Scholar
  3. 3.
    Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333–41.CrossRefGoogle Scholar
  4. 4.
    Biswas S, Brunel JM, Dubus JC, et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10:917–34.CrossRefGoogle Scholar
  5. 5.
    Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30:1279–91.CrossRefGoogle Scholar
  6. 6.
    Akers KS, Rowan MP, Niece KL, et al. Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;59:46–52.CrossRefGoogle Scholar
  7. 7.
    Gounden R, Bamford C, van Zyl-Smit R, et al. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis. 2009;9:1–6.CrossRefGoogle Scholar
  8. 8.
    Coulthard KP, Peckham DG, Conway SP, et al. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations. J Cyst Fibros. 2007;6:125–30.CrossRefGoogle Scholar
  9. 9.
    Cao G, Liang X, Zhang J, et al. Vancomycin serum trough concentration vs. clinical outcome in patients with gram-positive infection: a retrospective analysis. J Clin Pharm Ther. 2015;40:640–4.CrossRefGoogle Scholar
  10. 10.
    Sorlí L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380.CrossRefGoogle Scholar
  11. 11.
    Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother. 2003;47:1364–70.CrossRefGoogle Scholar
  12. 12.
    Li J, Milne RW, Nation RL, et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;761:167–75.CrossRefGoogle Scholar
  13. 13.
    Gobin P, Lemaître F, Marchand S, et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2010;54:1941–8.CrossRefGoogle Scholar
  14. 14.
    Bai L, Ma Z, Yang G, et al. A simple HPLC method for the separation of colistimethate sodium and colistin sulphate. J Chromatogr Sep Tech. 2011;02:2–5.CrossRefGoogle Scholar
  15. 15.
    Sorlí L, Luque S, Segura C, et al. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis. 2017;17:1–9.CrossRefGoogle Scholar
  16. 16.
    Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis. 2017;64:565–71.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Sriramulu Manivannan Vithunes
    • 1
  • Sathiyanathan Priyanka
    • 1
  • Johncy Jose
    • 1
  • Nitha Thankam Sajeev
    • 1
  • Ranganathan Hariprasad
    • 2
  • Gurusamy Venu
    • 3
  • Karthik Siram
    • 4
  • Veintramuthu Sankar
    • 4
    Email author
  1. 1.Department of Pharmacy PracticePSG College of PharmacyCoimbatoreIndia
  2. 2.Department of Pharmaceutical AnalysisPSG College of PharmacyCoimbatoreIndia
  3. 3.Department of Nephrology, PSG HospitalsPSG Institute of Medical Sciences and ResearchCoimbatoreIndia
  4. 4.Department of PharmaceuticsPSG College of PharmacyCoimbatoreIndia

Personalised recommendations